Dr. Carbone has served on several NCI grant review panels, including the clinical program project parent committee. He has served on organizing committees for both ASCO and AACR and the Board of Scientific Counselors for the NCI, is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). His research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms and gene therapy. Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics. His clinical specialty is lung cancer.